Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:10 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 249 matching trials from the live ClinicalTrials.gov search.
Conditions
Obsessive-Compulsive Disorder
Interventions
D-Cycloserine, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
7 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Los Angeles, California
Completed Phase 4 Interventional Results available

Vilazodone for Separation Anxiety Disorder

NCT01999920
Conditions
Separation Anxiety Disorder
Interventions
Vilazodone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Conditions
Orthostatic Hypotension, Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy
Interventions
automated abdominal binder, Sham binder, Placebo, Midodrine
Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
40 Years to 80 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Angina Pectoris
Interventions
T89
Drug
Lead sponsor
Tasly Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Beverly Hills, California • Corona, California + 11 more
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Methamphetamine Dependence, Methamphetamine Abuse, Substance Abuse
Interventions
Placebo, Varenicline
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Houston, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Neuroscience-Informed Treatment Development for Adolescent Alcohol Use

NCT03238300
Conditions
Alcohol Drinking, Control
Interventions
N-Acetylcysteine, Placebo Oral Capsule
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
15 Years to 19 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Conditions
Premenstrual Dysphoric Disorder (PMDD)
Interventions
sertraline 50 mg daily, Placebo Oral Tablet
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
288 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
2
States / cities
Baltimore, Maryland • Charlottesville, Virginia
Conditions
Parkinsons Disease
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Daniel Burdick, MD
Individual
Eligibility
30 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Kirkland, Washington
Terminated Phase 2 Interventional Results available

Study of Sulfasalazine in Treating Painful Neuropathy

NCT01667029
Conditions
Painful Neuropathy
Interventions
Sulfasalazine, placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Cholinergic Health After Menopause (CHAMP)

NCT04129060
Conditions
Postmenopausal Symptoms, Aging, Alzheimer Disease
Interventions
Cholinergic antagonist
Drug
Lead sponsor
University of Vermont
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Nashville, Tennessee • Burlington, Vermont
Conditions
Periodontitis
Interventions
20 mg doxycycline hyclate, Placebo
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
45 Years to 70 Years · Female only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Lincoln, Nebraska • Stony Brook, New York
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin, Oral Contraceptive Pill, Lifestyle Management Program, Quality of Life Questionnaire, Oral Glucose Tolerance Test, Blood work, Abdominal Ultra Sound, Dual-energy x-ray absorptiometry (DEXA scan), placebo
Drug · Behavioral · Procedure
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 18 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Rochester, New York
Conditions
Obsessive-compulsive Disorder
Interventions
Cognitive-behavioral therapy, d-cycloserine, Pill placebo
Behavioral · Drug
Lead sponsor
University of South Florida
Other
Eligibility
7 Years to 17 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
2
States / cities
St. Petersburg, Florida • Cambridge, Massachusetts
Conditions
Uncontrolled Partial Epilepsy, Ictal Hypoventilation
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Sacramento, California
Completed Not applicable Interventional Results available

Gulf War Digestive Health Study

NCT00680836
Conditions
Irritable Bowel Syndrome, Small Intestinal Bacterial Overgrowth
Interventions
Placebo, Rifaximin
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
35 Years to 72 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Lung Diseases, Lung Cancer, Protection Against
Interventions
Curcumin C3 complex®, Lovaza®, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
55 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Ocular Albinism (OA), Oculocutaneous Albinism (OCA)
Interventions
Lutein plus Zeaxanthin, Placebo
Dietary Supplement
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Influenza
Interventions
Nitazoxanide, Placebo
Drug
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
12 Years to 65 Years
Enrollment
624 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Elmira, New York
Completed Not applicable Interventional Results available

Anti-Inflammatory Treatment of Schizophrenia

NCT01514682
Conditions
Schizophrenia
Interventions
Anti-inflammatory Combination Therapy, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Coronary Artery Disease Risk Factors Multiple, Coronary Artery Disease Progression, Prevention & Control, Premature Atherosclerosis
Interventions
Rosuvastatin 20 Mg Oral Tablet, Colchicine 0.5 MG Oral Tablet Once Daily, Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
30 Years to 60 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 18 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins

NCT00995670
Conditions
Hyperglycemia
Interventions
5% dextrose, Vitamin C, Simvastatin, Sevoflurane
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 35 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Conditions
Hot Flashes
Interventions
Gabapentin Extended-Release (G-ER) 1200 mg, Gabapentin Extended-Release (G-ER) 1800 mg, Placebo
Drug
Lead sponsor
Depomed
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
45
States / cities
Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 40 more
Conditions
Anxiety Disorders, Mood Disorders, Insomnia, Nightmares
Interventions
Behavioral Sleep Intervention, Prazosin, Placebo
Behavioral · Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania